IceCure Medical Presents Positive Breast Cancer Study Results

Ticker: ICCM · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1584371

Sentiment: neutral

Topics: medical-devices, breast-cancer, clinical-trials, press-release

TL;DR

IceCure's ProSense shows promise in breast cancer treatment, with 5 studies presented at European Congress.

AI Summary

On September 30, 2025, IceCure Medical Ltd. announced positive results from five independent studies on its ProSense system at the European Society of Breast Imaging Congress 2025. The presented data highlighted the system's potential in de-escalating care for breast cancer patients.

Why It Matters

The positive study results for IceCure's ProSense system could lead to improved treatment options and de-escalation of care for breast cancer patients, potentially impacting patient outcomes and healthcare costs.

Risk Assessment

Risk Level: low — This filing is a routine report of foreign private issuer information and does not contain significant new financial or operational developments.

Key Players & Entities

FAQ

What is the main topic of the press release furnished by IceCure Medical Ltd. on September 30, 2025?

The press release discusses positive results from five independent studies on IceCure's ProSense® system presented at the European Society of Breast Imaging Congress 2025, focusing on de-escalation of care in breast cancer.

What is the Commission File Number for IceCure Medical Ltd.'s filing?

The Commission File Number is 001-40753.

What form is IceCure Medical Ltd. filing?

IceCure Medical Ltd. is filing a Form 6-K, which is a Report of Foreign Private Issuer.

Where is IceCure Medical Ltd.'s principal executive office located?

The principal executive office is located at 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel.

Does IceCure Medical Ltd. file annual reports under Form 20-F or Form 40-F?

IceCure Medical Ltd. files annual reports under Form 20-F.

Filing Stats: 328 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2025-09-30 09:27:46

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: September 30, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing